Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450

Biochemical and Biophysical Research Communications
D ServentM Lenfant

Abstract

Glyceryl trinitrate was denitrated by rat liver microsomes in the presence of NADPH with formation of a mixture of glyceryl dinitrates and glyceryl mononitrates. The highest activity was obtained under anaerobic conditions and the reaction was inhibited by O2 indicating that it is a reductive denitration. It was also inhibited by CO, metyrapone and miconazole showing that it was catalyzed by cytochrome P-450. Finally the formation of the cytochrome P-450-Fe(II)-NO complex during this reaction was shown by visible spectroscopy. These data demonstrate that microsomal reductive denitration of glyceryl trinitrate is catalyzed by cytochrome P-450 and can be involved in the formation of the endothelium-derived relaxing factor (EDRF = nitric oxide).

References

Jul 15, 1975·FEBS Letters·R E EbelJ A Peterson
Sep 1, 1977·Clinical Pharmacology and Therapeutics·F J Di CarloI W Davidson
Jun 1, 1978·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·R KahlK J Netter
Jan 1, 1976·Annual Review of Pharmacology and Toxicology·P Needleman
Dec 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·L J IgnarroG Chaudhuri
Dec 1, 1987·Toxicology and Applied Pharmacology·H KruszynaD E Wilcox
Feb 1, 1982·Biochemical Pharmacology·H J AhrV Ullrich
Sep 1, 1981·European Journal of Biochemistry·P KremersJ E Gielen

❮ Previous
Next ❯

Citations

Oct 1, 1994·Cardiovascular Drugs and Therapy·K E Torfgård, J Ahlner
Jan 26, 1993·Biochemical Pharmacology·B MayerK Schmidt
Jan 7, 1993·Biochemical Pharmacology·B J McDonald, B M Bennett
Jan 1, 1993·Mutation Research·C M MaragosR K Elespuru
Jul 1, 1994·Trends in Pharmacological Sciences·B M BennettW C Simon
Dec 23, 1999·European Journal of Pharmacology·P AgvaldM G Persson
Jun 23, 2001·Biochimica Et Biophysica Acta·J J DoelR Harrison
Mar 10, 2001·BJOG : an International Journal of Obstetrics and Gynaecology·L C LauS C Ng
Jul 12, 2002·Journal of Pharmaceutical and Biomedical Analysis·Marina CariniRoberto Maffei Facino
Feb 1, 1997·Nature Biotechnology·A GoelS K Dube
Jan 13, 2001·British Journal of Pharmacology·D Martens, G Kojda
Jan 30, 2002·British Journal of Pharmacology·Per AgvaldLars E Gustafsson
Oct 8, 1999·Journal of Cardiovascular Pharmacology·G BerkenboomJ Fontaine
Mar 21, 2002·Journal of Cardiovascular Pharmacology·Vincenzo MollaceDaniela Salvemini
Jan 1, 1992·British Journal of Clinical Pharmacology·E Bassenge
Nov 1, 1993·British Journal of Pharmacology·D SalveminiE Anggard
Feb 27, 2003·Clinical Pharmacokinetics·Satoru Hashimoto, Atsuko Kobayashi
Apr 25, 2000·Biochemical and Biophysical Research Communications·J J DoelR Harrison
Dec 20, 2011·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Michele PauloLusiane M Bendhack
Feb 17, 2009·Medicinal Research Reviews·Ernst E van FaassenMark T Gladwin
Sep 24, 1992·The American Journal of Cardiology·E Bassenge, J Zanzinger
Mar 1, 1995·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·N OgawaT Satoh
Mar 15, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Modesto de CandiaCosimo D Altomare
Sep 9, 1993·The American Journal of Cardiology·H L Fung
Oct 7, 2008·Reproductive Sciences·Immacolata BlasiFabio Facchinetti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.